Lanabecestat - CAS 1383982-64-6
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C26H28N4O
Molecular Weight:
412.53
COA:
Inquire
Targets:
β-secretase
Description:
Lanabecestat, also referred to AZD3293,is an orally active and highly permeable potent inhibitor of human β-secretase 1 in clinical development for the treatment of Alzheimer disease with a Ki of 0.4 nM.
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
An oral beta-secretase 1 cleaving enzyme (BACE) inhibitor (Ki= 0.4 nM)
Synonyms:
(1r,4r)-4-methoxy-5''-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine; 4-methoxy-5'-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro(cyclohexane-1,2'-inden-1',2'-imidazol)-4'-amine; AZD3293
Solubility:
DMSO
Storage:
Store in a cool and dry place (or refer to the Certificate of Analysis).
MSDS:
Inquire
Boiling Point:
621.9±65.0 ℃ at 760 Torr
Density:
1.23±0.1 g/cm3
InChIKey:
WKDNQONLGXOZRG-BOPKNSRXSA-N
InChI:
1S/C26H28N4O/c1-4-5-18-12-21(16-28-15-18)19-6-7-20-14-25(10-8-22(31-3)9-11-25)26(23(20)13-19)29-17(2)24(27)30-26/h6-7,12-13,15-16,22H,8-11,14H2,1-3H3,(H2,27,30)/t22?,25?,26-/m0/s1
Canonical SMILES:
CC#CC1=CC(=CN=C1)C2=CC3=C(CC4(C35N=C(C(=N5)N)C)CCC(CC4)OC)C=C2
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related β-secretase Products


TAK-070
(CAS: 365276-12-6)

TAK-070, under the IUPAC name 2-​Naphthaleneethanamin​e, 6-​([1,​1'-​biphenyl]​-​4-​ylmethoxy)​-​1,​2,​3,​4-​tetrahydro-​N,​N-​dimethyl-​, hydrochloride, hydrat...

AZD3839
(CAS: 1227163-56-5)

AZD3839, with the potential to treat Alzheimer’s disease, was reported as a selective BACE1 inhibitor (IC50=4.8μM) for which concentration-dependent lowering of...

CAS 244081-42-3 Rafabegron

Rafabegron
(CAS: 244081-42-3)

Rafabegron is a potent and selective beta3-adrenoceptor agonist.

CAS 1262036-50-9 LY2886721

LY2886721
(CAS: 1262036-50-9)

LY2886721, under the IUPAC name N-(3-(2-amino-4a,5,7,7a-tetrahydro-4H-furo(3,4-d)(1,3)thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide, is the first oral sma...

AZD3293
(CAS: 1628076-74-3)

AZD3293, a spiro compound, has been found to be a β-secretase inhibitor that has good blood-brain barrier penetration and could probably be significant in studi...

CAS 1262036-49-6 LY 2886721 hydrochloride

LY 2886721 hydrochloride
(CAS: 1262036-49-6)

LY 2886721 hydrochloride is the first oral inhibitor of human β-secretase (BACE-1) with the potential to treat Alzheimer's Disease.

CAS 797035-11-1 BACE-1 Inhibitor

BACE-1 Inhibitor
(CAS: 797035-11-1)

BACE-1 Inhibitor is a potent, selective and cell-permeable inhibitor of human β-secretase (BACE-1) binding to the active site of BACE-1. It inhibits secretion o...

Verubecestat
(CAS: 1286770-55-5)

Verubecestat, a iminothiadiazine dioxide compound, is an oral BACE1 inhibitor originated by Merck & Co. It can bind significantly to β-secretase. Verubecestat h...

CAS 989-51-5 EGCG

EGCG
(CAS: 989-51-5)

EGCG, also called Epigallocatechin gallate, under the IUPAC name [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxy...

CAS 1383982-64-6 Lanabecestat

Lanabecestat
(CAS: 1383982-64-6)

Lanabecestat, also referred to AZD3293,is an orally active and highly permeable potent inhibitor of human β-secretase 1 in clinical development for the treatmen...

PF-05297909

PF-05297909, is a BACE inhibitor developed by Pfizer. Phase 1

AMG-8718
(CAS: 1215868-94-2)

This active molecular is a potent BACE1 inhibitor that is a potential target for the treatment of Alzheimer's disease. AMG-8718 produced significantly reduction...

RG7129
(CAS: 1628077-06-4)

RG7129, developed by Roche, inhibit BACE to treat Alzheimer's disease. Phase-I

CAS 1194044-20-6 LY2811376

LY2811376
(CAS: 1194044-20-6)

LY2811376, under the IUPAC name (4S)-4-(2,4-difluoro-5-pyrimidin-5-ylphenyl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine, is the first orally available non-peptidi...

CTS-21166

CTS-21166, the selective BACE1 inhibitor whose structure is not revealed, reduce brain Aβ levels by over 35% and plaque load by 40%. Phase 1 IC50=1.2–3.6 nM (ce...

HPP854

HPP854, developed by High Point Pharmaceuticals, is a small molecule BACE1 protein inhibitor. Phase 1

E2609

E2609, developed by Eisai Inc, is a novel, small molecule, BACE1 inhibitor that has been shown in nonclinical studies to inhibit the production of Aβ40 and Aβ42...

VTP-37948

VTP-37948, also called BI 1181181, being clinically developed with Boehringer Ingelheim and Vitae Pharmaceuticals, is a is an inhibitor targeted to the catalyti...

CAS 1254166-60-3 Imidazo[1,2-a]pyridine-2-carboxamide, 6-chloro-N-[6-(phenylmethoxy)-1H-benzimidazol-2-yl]-

Imidazo[1,2-a]pyridine-2-carboxamide, 6-
(CAS: 1254166-60-3)

An inhibitor of β-site amyloid precursor protein-cleaving enzyme (BACE)

AZD3839
(CAS: 1227163-84-9)

AZD3839, also called CHEMBL2177913, as a a potent BACE1 inhibitor it is a clinical candidate for the treatment of Alzheimer's disease. Studies indicate that the...

Chemical Structure

CAS 1383982-64-6 Lanabecestat

Quick Inquiry

Verification code

Featured Items